Emergent Biosolutions Inc (EBS) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.27 earnings per share for the quarter, missing the analyst consensus estimate by $-0.10. Analysts had a consensus of $-0.17. The company posted revenue of $101.49 million in the period, compared to analysts expectations of $111.12 million. The company’s revenue was down -19.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 EPS.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Shares were Reiterated by Singular Research on Jun 28, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $44 .
Emergent Biosolutions Inc closed down -0.5 points or -1.61% at $30.47 with 7,87,457 shares getting traded on Tusday. Post opening the session at $31.04, the shares hit an intraday low of $30.41 and an intraday high of $31.2 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 7, 2016, George A Joulwan (director) sold 4,700 shares at $44.12 per share price. According to the SEC, on Jun 3, 2016, Daniel Abdun-nabi (President & CEO) sold 8,699 shares at $43.74 per share price. On May 27, 2016, Fuad El-hibri (Chairman) sold 9,835 shares at $43.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.